128 related articles for article (PubMed ID: 38307814)
1. Multiparameter spectral CT-based radiomics in predicting the expression of programmed death ligand 1 in non-small-cell lung cancer.
Zheng XX; Ma YQ; Cui YQ; Dong SS; Chang FX; Zhu DL; Huang G
Clin Radiol; 2024 Apr; 79(4):e511-e523. PubMed ID: 38307814
[TBL] [Abstract][Full Text] [Related]
2. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
3. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
[TBL] [Abstract][Full Text] [Related]
4. Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
Wen Q; Yang Z; Dai H; Feng A; Li Q
Front Oncol; 2021; 11():620246. PubMed ID: 34422625
[TBL] [Abstract][Full Text] [Related]
5. A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
Lim CH; Koh YW; Hyun SH; Lee SJ
Anticancer Res; 2022 Dec; 42(12):5875-5884. PubMed ID: 36456151
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Machine Learning-Based Model Using CT Radiomics for Predicting Immune Checkpoint Inhibitor-related Pneumonitis in Patients With NSCLC Receiving Anti-PD1 Immunotherapy: A Multicenter Retrospective CaseControl Study.
Zhang GY; Du XZ; Xu R; Chen T; Wu Y; Wu XJ; Liu S
Acad Radiol; 2024 May; 31(5):2128-2143. PubMed ID: 37977890
[TBL] [Abstract][Full Text] [Related]
7. Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients.
Bracci S; Dolciami M; Trobiani C; Izzo A; Pernazza A; D'Amati G; Manganaro L; Ricci P
Radiol Med; 2021 Nov; 126(11):1425-1433. PubMed ID: 34373989
[TBL] [Abstract][Full Text] [Related]
8. Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Nogova L; Araceli T; Schmidt NO; Ruge MI; Goldbrunner R; Proescholdt M; Grau S; Lohmann P
J Neurooncol; 2023 Jul; 163(3):597-605. PubMed ID: 37382806
[TBL] [Abstract][Full Text] [Related]
9. CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer.
Wang J; Wang J; Huang X; Zhou Y; Qi J; Sun X; Nie J; Hu Z; Wang S; Hong B; Wang H
BMC Med Imaging; 2024 Feb; 24(1):45. PubMed ID: 38360550
[TBL] [Abstract][Full Text] [Related]
10. [Construction of A Nomogram Prediction Model for PD-L1 Expression
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
Hao L; Wang L; Zhang M; Yan J; Zhang F
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
[TBL] [Abstract][Full Text] [Related]
11. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
[TBL] [Abstract][Full Text] [Related]
12. Can PD-L1 expression be predicted by contrast-enhanced CT in patients with gastric adenocarcinoma? a preliminary retrospective study.
Gu X; Yu X; Shi G; Li Y; Yang L
Abdom Radiol (NY); 2023 Jan; 48(1):220-228. PubMed ID: 36271155
[TBL] [Abstract][Full Text] [Related]
13. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
Jiang M; Sun D; Guo Y; Guo Y; Xiao J; Wang L; Yao X
Acad Radiol; 2020 Feb; 27(2):171-179. PubMed ID: 31147234
[TBL] [Abstract][Full Text] [Related]
14. A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer.
Gong J; Bao X; Wang T; Liu J; Peng W; Shi J; Wu F; Gu Y
Oncoimmunology; 2022; 11(1):2028962. PubMed ID: 35096486
[TBL] [Abstract][Full Text] [Related]
15. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
16. Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images.
Wang C; Ma J; Shao J; Zhang S; Liu Z; Yu Y; Li W
Front Immunol; 2022; 13():813072. PubMed ID: 35250988
[TBL] [Abstract][Full Text] [Related]
17. A computed tomography-based radiomics signature for predicting expression of programmed death ligand 1 in head and neck squamous cell carcinoma.
Zheng YM; Yuan MG; Zhou RQ; Hou F; Zhan JF; Liu ND; Hao DP; Dong C
Eur Radiol; 2022 Aug; 32(8):5362-5370. PubMed ID: 35298679
[TBL] [Abstract][Full Text] [Related]
18. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.
Chen M; Lu H; Copley SJ; Han Y; Logan A; Viola P; Cortellini A; Pinato DJ; Power D; Aboagye EO
J Thorac Oncol; 2023 Jun; 18(6):718-730. PubMed ID: 36773776
[TBL] [Abstract][Full Text] [Related]
19. CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study.
Jiang Z; Dong Y; Yang L; Lv Y; Dong S; Yuan S; Li D; Liu L
J Digit Imaging; 2021 Oct; 34(5):1073-1085. PubMed ID: 34327623
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a CT-Based Signature for the Prediction of Distant Metastasis Before Treatment of Non-Small Cell Lung Cancer.
Tao J; Lv R; Liang C; Fang J; Liu D; Lan X; Huang H; Zhang J
Acad Radiol; 2022 Feb; 29 Suppl 2():S62-S72. PubMed ID: 33402298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
